Can Adempas meet Bayer's growth expectations after a canceled trial?

Adempas

Bayer has long counted pulmonary arterial hypertension newcomer Adempas among its Big 5 growth products. But after a slow start and a recently halted trial, maybe it shouldn’t.

Last week, the German pharma shut down a trial of the med in PAH patients with idiopathic interstitial pneumonias. The trial's independent data monitoring committee recommended the move, noting that patients in the Adempas arm could experience an increased risk of death or other serious adverse events.

The move scuttled hopes of a label expansion down the line, which could have swelled sales that right now need a boost. EvaluatePharma now predicts Adempas will rack up just $459 million in 2022 sales--a far cry from the $870 million analysts once expected to see by 2018, EPVantage notes.

3-Day Conference

6th Promotional Review Committee Compliance & Best Practices Conference

The leading U.S. event devoted to building the skills, speed and teamwork of your promotional review committee members will take place May 15–17, 2019 in Chicago. The conference is set to bring together more than 75 professionals to ensure your PRC is prepared to generate, collect and constructively act on expert comments for your entire drug and device portfolio.

Meanwhile, there’s new competition on the block for the German pharma, too. Rival Actelion, out to make up sales for aging Tracleer, has done just that with PAH newcomer Opsumit, which netted CHF 516 million ($525 million) in 2015. The Swiss biotech also recently launched blockbuster hopeful Uptravi, another baseline therapy that it hopes will help bridge the gap between Opsumit and its late-stage treatment, Veletri.

With all that in mind, it may be hard for Bayer to keep counting Adempas as a high-growth product among the likes of stars Xarelto, a blood thinner it shares with Johnson & Johnson, and Eylea, an eye therapy it markets with Regeneron. The Leverkusen-based drugmaker has been pegging those three treatments, as well as cancer meds Xofigo and Stivarga, as the future of its pharma portfolio as it transforms into a strictly life sciences-based company.

Luckily for Bayer, though, some analysts think its other quick-launchers can pick up the slack. Bernstein analyst Ronny Gal, for one, has forecast €2.5 billion in Eylea sales by 2020, "significantly ahead of the €1.5 billion guided by Bayer.”

And Stivarga looks as if it could soon be in for another approval, too. Earlier this month, Bayer announced that a Phase III study in patients with unresectable liver cancer had met its primary endpoint, topping placebo in extending overall survival among sufferers whose disease had progressed after treatment with Bayer’s own blockbuster Nexavar.

- read Bayer's release
- get more from EPVantage (reg. req.)

Special Report: The top 15 pharma companies by 2014 revenue - Bayer

Related Articles:
Bayer plots Stivarga expansion with new top-line data in hand
Actelion exceeds profit estimates as Opsumit, Uptravi make up for aged Tracleer
Eylea may be giving Regeneron trouble in the U.S., but it's pumping up for Bayer in EU
With Big 5, Bayer aims for 8% annual pharma growth through 2016
Aiming for big growth in top 5 meds, Bayer will stake an extra $600M on marketing, R&D

Suggested Articles

With a deal for the digoxin portfolio of Poland's Nobilus, C2 Pharma will have two supplies of API for making the sometimes difficult-to-get drug.…

A North Carolina federal jury found that Puma maliciously defamed Eshelman amid a proxy fight that began in late 2015.

Merck KGaA says it will invest €1 billion in its headquarters site in Darmstadt, Germany, as part of a five-year agreement reached with workers there.